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Abstract
Background: Fibromyalgia syndrome displays sympathetically maintained pain features such as
frequent post-traumatic onset and stimuli-independent pain accompanied by allodynia and
paresthesias. Heart rate variability studies showed that fibromyalgia patients have changes
consistent with ongoing sympathetic hyperactivity. Norepinephrine-evoked pain test is used to
assess sympathetically maintained pain syndromes. Our objective was to define if fibromyalgia
patients have norepinephrine-evoked pain.
Methods: Prospective double blind controlled study. Participants: Twenty FM patients, and two
age/sex matched control groups; 20 rheumatoid arthritis patients and 20 healthy controls. Ten
micrograms of norepinephrine diluted in 0.1 ml of saline solution were injected in a forearm. The
contrasting substance, 0.1 ml of saline solution alone, was injected in the opposite forearm.
Maximum local pain elicited during the 5 minutes post-injection was graded on a visual analog scale
(VAS). Norepinephrine-evoked pain was diagnosed when norepinephrine injection induced greater
pain than placebo injection. Intensity of norepinephrine-evoked pain was calculated as the
difference between norepinephrine minus placebo-induced VAS scores.
Results: Norepinephrine-evoked pain was seen in 80 % of FM patients (95% confidence intervals
56.3 – 94.3%), in 30 % of rheumatoid arthritis patients and in 30 % of healthy controls (95%
confidence intervals 11.9 – 54.3) (p < 0.05). Intensity of norepinephrine-evoked pain was greater
in FM patients (mean ± SD 2.5 ± 2.5) when compared to rheumatoid arthritis patients (0.3 ± 0.7),
and healthy controls (0.3 ± 0.8) p < 0.0001.
Conclusions: Fibromyalgia patients have norepinephrine-evoked pain. This finding supports the
hypothesis that fibromyalgia may be a sympathetically maintained pain syndrome.
Background
Several groups of investigators, using heart rate variability
analysis have shown that fibromyalgia (FM) patients have
changes consistent with persistent sympathetic hyperac-
tivity and concurrent hypo-reactivity to orthostatic stress
[1–6]. This body of evidence led to the proposal that FM
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may be a sympathetically maintained pain syndrome [7].
This pathogenesis would explain the peculiar pain syn-
drome that FM patients display, as well as the remaining
manifestations that this illness exhibits in different organs
and systems of the body [8].
Norepinephrine (NE)-evoked pain is the most widely
used clinical research test to define sympathetically main-
tained pain syndromes. Several studies have shown that
different types of neuropathic pain previously submissive
to sympatholytic therapy are rekindled by cutaneous ap-
plication of NE. Ali et al described 12 patients with reflex
sympathetic dystrophy (complex regional pain syndrome
type I) in whom NE application rekindled pain [9]. Tore-
bjork et al. described that NE application can aggravate
the pain in some, but not all sympathetically maintained
pain patients [10]. Davis et al reported that the alpha 2-
adrenergic agonist clonidine, delivered by transdermal
patches relieves hyperalgesia in sympathetically main-
tained pain [11]. Clonidine activates pre-synaptic adren-
ergic autoreceptors resulting in a reduction of
norepinephrine release. This effectively decreases activa-
tion of the post-synaptic alpha 1 receptors.
Methods
Participants
We studied 20 patients with FM and two age (+/- 5 years)
and sex matched control groups, namely: 20 patients with
rheumatoid arthritis (RA) and 20 apparently healthy per-
sons. The eligibility criteria for the 3 different groups were
as follows: for FM patients, to fulfill the 1990 ACR classi-
fication criteria for this syndrome [12] and absence of co-
morbidity. For RA; to fulfill the corresponding
classification criteria [13] and to have an active disease. An
exclusion clause for both control groups was the presence
o f  w i d e s p r e a d  p a i n  a n d / o r  m o r e  t h a n  1 1  F M  t e n d e r
points.
Analgesic/anti-inflammatory medications were not al-
lowed in the immediate 24 hr. before the study. All sub-
jects signed an informed consent form. The Human
Research Committee of our Institute approved the proto-
col.
Interventions
The day of the study, subjects filled out a 10 cm visual an-
alog scale for pain, fatigue, sleep difficulties, morning
stiffness and disability, as well as a structured question-
naire about the presence of the distinctive features of FM
according to the ACR criteria [12] and of chronic fatigue
syndrome according to the International Study Group cri-
teria. [14]. Norepinephrine (NE) was administered under
a double blind protocol. Using insulin syringes with 29
gauge needles, 10 micrograms of NE diluted in 0.1 ml of
normal saline solution or 0.1 ml of normal saline solution
alone were injected subcutaneously in the volar aspect of
a forearm. The contrasting substance was injected in the
opposite forearm.
Objective
To define if subcutaneous injections of NE induces pain in
FM patients.
Outcome measures
Subjects graded on a 10 cm visual analog scale (VAS), the
maximum local pain elicited during the 5 minutes post-
injection. NE-evoked pain was diagnosed when NE injec-
tion induced greater pain than placebo injection. Intensity
of NE-evoked pain was calculated as the difference be-
tween the VAS score in the NE-injected forearm minus
VAS score in the placebo-injected forearm.
Associated adverse events were recorded.
Sample size
It was arbitrarily set at 20 participants per group. This is a
pilot study, we had no pre-trial information on the expect-
ed response to NE for RA patients and FM patients.
Randomization, sequence generation
A coin flip was used to allocate the intervention sequence
placebo-NE for each participant. Left forearms were inject-
ed first.
Allocation concealment and blinding
The physician who performed the injections was blinded
as to the substance she was administering, she was not
blinded as to patient's diagnosis. Injected substance iden-
tity was concealed until after outcomes were measured.
Statistical methods
Mean and standard deviation are used for descriptive val-
ues. Binomial distributed values are calculated as propor-
tion with its 95% confidence intervals. Chi square analysis
is used to compare qualitative variables. One-way analysis
of variance to compare continuous variables. Bonferroni's
multiple comparison test to define inter-group differenc-
es. P values < 0.05 were considered significant.
Results
Baseline data
It is outlined in table 1. Ninety percent of FM patients
were female. Their mean age was 43 years.
When compared to RA patients, FM subjects had similar
VAS scores in pain perception and morning stiffness. Nev-
ertheless they had higher scores in fatigue, sleep distur-
bances and disability perception.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/2
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Outcomes and estimation
Eighty percent of FM patients had NE-evoked pain accord-
ing to our definition, in contrast 30% of RA patients and
30% of normal controls had such response (p < 0.05) (fig-
ure 1). Likewise NE-evoked pain intensity was greater in
FM group (mean +/- SD 2.5 +/- 2.5) when compared to RA
patients (0.3 +/- 0-7) and healthy controls (0.3 +/- 0.8) p
< 0.0001. (Figure 2).
Response to placebo in FM group (mean +/- SD 0.5 +/-
1.3) was not different when compared to RA group (0.1 +/
- 0.2) p = 0.07.
Adverse events
Pain induction was severe in two FM patients injected
with NE (figure 2). Other adverse events are outlined in
table 2. Notable was a peculiar spreading of pain to other
areas of the extremity seen in 8/20 of FM patients after NE
injection.
Discontinued medications
Table 3 shows prescribed non-steroidal analgesic/anti-in-
flammatory drugs and centrally acting medications with
their corresponding plasma half-life. Analgesic/anti-in-
flammatory drugs were discontinued at least 24 hours be-
fore the study.
Discussion
Interpretation
Our double blind study demonstrates that most FM pa-
tients have NE-evoked pain. This type of response was sig-
nificantly different from the response observed in another
Table 1: Baseline Data of Fibromyalgia Patients and Two Age/Sex Matched Control Groups
Fibromyalgia Rheumatoid arthritis Healthy controls
(n = 20) (n = 20) (n = 20)
Age (mean ± SD) 43.0 ± 15.2 45.4 ± 13.1 42.1 ± 14.8
Gender (F/M) (18/2) (18/2) (18/2)
Total fibromyalgia points, (mean ± SD) 16.8 ± 1.9* 1.3 ± 1.7 0.7 ± 1.5
VAS score, (mean ± SD)
Pain 6.5 ± 2.5** 4.3 ± 2.5 0 ± 0
Fatigue 7.2 ± 2.4* 2.6 ± 2.5 0.5 ± 1.3
Sleep disturbances 5.9 ± 2.6* 2.0 ± 2.5 0.2 ± 1.1
Morning stiffness 4.8 ± 3.7** 2.4 ± 2.6 0.2 ± 0.7
Disability 7.1 ± 2.2* 3.1 ± 3.2 0.2 ± 0.6
Symptoms, % of patients (95% confidence interval)
Anxiety 90 (68.3–98.8)* 45 (23.0–68.5) 40(19.1–63.9)
Headache 90 (68.3–98.8)* 35(15.4–59.2) 25(8.7–49.1)
Weakness 90 (68.3–98.8)* 45 (23.0–68.5) 10(1.2–31.7)
Forgetfulnes 85(62.1–96.8)* 50 (27.2–72.8) 15 (3.2–37.9)
Paresthesias 85(62.1–96.8)* 35(15.4–59.2) 30(11.9–54.3)
Irritable bowel 65 (40.8–84.6)* 10(1.2–31.7) 20 (5.7–43.7)
Sicca syndrome 53 (28.9–75.5)** 45 (23.0–68.5) 10(1.2–31.7)
Sore throat 45 (23.0–68.5)** 25(8.7–49.1) 5(0.1–24.9)
Acute onset 40(19.1–63.9)* 5 (0.1–24.9) 0(0–16.8)
Cold hands 40(19.1–63.9)** 15(3.2–37.9) 0(0–16.8)
Low grade fever 20 (5.7–43.7)** 0(0–16.8) 0(0–16.8)
Lymph gland enlargement 5 (0.1–24.9) 5 (0.1–24.9) 0(0–16.8)
VAS = 10 cm visual analog scale
*=p < 0.05 vs both control groups
** = p < 0.05 vs healthy controls onlyBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/2
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chronic painful condition, rheumatoid arthritis, and also
different from healthy controls. Furthermore, the intensi-
ty of NE-evoked pain was greater in FM subjects when
compared to the other two control groups. These results
give experimental support to the notion that FM is a sym-
pathetically maintained pain syndrome.
Generalizability
We recognize limitations in our study; although we used
a double blind protocol, nevertheless patient's diagnosis
(FM, RA or healthy control) could not be blinded to the
physician who performed the injections. We believe this
fact did not bias the results since all participants were giv-
en the same information on what to expect from the injec-
tions. Such information was basically what was written in
the consent form.
Our study did not explore the specificity of the hyperalge-
sic response to NE in the FM group. To test this possibility
it would be necessary to first perform sympathetic block-
ade and latter attempt to rekindle pain with NE. Another
possible approach would be an additional intervention
injecting NE mixed with an adrenergic blocking agent.
Nevertheless, such approach has theoretical shortcomings
as some adrenergic blocking agents also have intrinsic an-
esthetic properties.
Figure 1
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Table 2: Number of cases with adverse events after norepinephrine (NE) and placebo injections
Fibromyalgia Rheumatoid Arthritis Healthy Controls
(n = 20) (n = 20) (n = 20)
placebo NE placebo NE placebo NE
Spreading of pain 08 0 0 0 0
Pale halo 03 0 1 0 1
Paresthesias 52 4 3 5 2
Palpitations 01 0 0 0 0
Sweating 01 0 0 0 0
Distal swelling 01 0 0 0 0BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/2
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The 24 hours period of analgesic/anti-inflammatory drugs
discontinuation may have been insufficient for the pa-
tients to be free of long acting medications effects. Like-
wise centrally acting drugs may have blunted the response
to NE. Nevertheless we believe these circumstances did
not impact the results as only 3 patients (2 with RA and 1
with FM) were taking long-acting compounds such as
piroxicam (table 3). Of the ten FM patients that were on
centrally acting drugs 7 had NE-evoked pain, similarly 9/
10 FM subjects that were not taking such drugs had NE-
evoked pain.
The injected dosages of 10 micrograms of NE were based
on what was previously reported in the neuropathic pain
literature and also on a pre-trial NE injections in ourselves
that demonstrated no untoward effects and no pain elici-
tation with this dosage. Future studies may find more ap-
propriate NE dosages as well as different routes of
administration such as transdermal patches, and perhaps
different dilutions to cover a wider area and thus possibly
better discriminate the hyperalgesic response of patients
from controls. We speculate about the possibility that
once perfected, NE-evoked pain may evolve into a useful
clinical test for FM.
Overall evidence
The first study of autonomic nervous system function in
FM was a controlled therapeutic trial reported by Bengts-
son and Bentgsson in 1988 [15]. They described that an-
esthetic blockade of the sympathetic stellate ganglion,
markedly decreased regional pain and tender points in
contrast to the lack of effect of sham placebo injection
into the neck area. Subsequently Vaeroy et al. using Dop-
pler probes showed that FM patients have diminished dis-
tal vasomotor response to acoustic or cold stimulation
[16]. With the introduction in recent years of a new pow-
erful technique, heart rate variability analysis, several
groups of investigators demonstrated that FM subjects
have changes consistent with relentless sympathetic hy-
peractivity with concurrent hypo-reactivity to stress. [1–
6]. This accumulated evidence led to propose that FM may
be a sympathetically maintained pain syndrome [7].
Sympathetically maintained pain is characterized by its
frequent post-traumatic onset, by the presence of chronic
stimuli-independent pain that is accompanied by allody-
nia, paresthesias and distal vasomotor changes. Typically,
this type of pain is diminished by sympathetic blockade
[17]. FM pain has such characteristics. It is well known
that FM syndrome has frequent post-traumatic onset par-
ticularly when the trauma is directed to neck area [18], a
site with unique superficial sympathetic ganglia network.
Pain in FM is clearly stimuli-independent, as no underly-
ing peripheral tissue damage has been identified. FM ten-
der points reflect a state of generalized allodynia [19].
Paresthesias are more frequent in FM when compared to
patients with other systemic rheumatic diseases [12]. In
FM there are distal vasomotor changes manifested as
pseudo-Raynaud phenomenon [16] and soft tissue swell-
ing. Finally as mentioned before, FM pain appears to be
submissive to sympatholytic maneuvers.
In addition to the pain syndrome, sympathetic hyperac-
tivity may explain other typical manifestations of FM such
as sleep problems, irritable bowel, sicca symptoms, and
anxiety [8]. The concurrent sympathetic hyporeactivity
Table 3: Prescribed non-steroidal anti-inflammatory drugs and centrally acting agents. (*) means that the drug was discontinued at least 
24 hrs before the study. Plasma half-life of each compound is also indicated.
Fibromyalgia Rheumatoid Arthritis
Drug Number of patients Plasma half-life (hours) Drug Number of patients Plasma half-life (hours)
clonazepam 6 20–60 acetaminophen* 4 4–6
acetaminophen* 5 4–6 celecoxib* 3 10–12
mianserin 2 21–61 diclofenac* 3 3–7
alprazolam 2 12–15 piroxicam* 2 34–50
bromazepam 1 20 clonazepam 1 20–60
triazolam 1 1.5–5.5 alprazolam 1 12–15
piroxicam* 1 34–50 indomethacin* 1 4–5
celecoxib* 1 10–12 aspirin* 1 2–3
ketoprofen* 1 1.5–4 rofecoxib* 11 7
fluoxetine 1 96–144 ibuprofen* 1 2–3
gabapentin* 1 5–9 gabapentin* 1 5–9BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/2
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that these patients display (probably due to a ceiling ef-
fect) provides a coherent explanation for their constant fa-
tigue [8]
Conclusion
FM patients have NE-evoked pain. This finding supports
the hypothesis that FM may be a sympathetically main-
tained pain syndrome.
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